TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05509777: A Phase 3, Multicenter, Randomized Clinical Study to Evaluate Mirikizumab in Pediatric Crohn's Disease

Sponsor: Eli Lilly and Company · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$587,880

Rescue Site Savings

+$391,920

Unlock Full NCT05509777 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05509777 Rescue Dossier →